Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation
Full Pivotal Data Suggests
The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.
